The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
iwCLL 2025 | Using disease profiling to identify potential therapeutic targets in Richter’s transformation
In this video, Erin Parry, MD, PhD, Dana-Farber Cancer Institute, Boston, MA, comments on advances in disease profiling that may lead to the identification of potential therapeutic targets in Richter’s transformation. Dr Parry highlights the role of advanced technologies, such as single-cell sequencing and spatial technologies, in enabling a deeper understanding of the differences between chronic lymphocytic leukemia (CLL) and Richter’s cells. This interview took place at the biennial International Workshop on Chronic Lymphocytic Leukemia (iwCLL) 2025 in Krakow, Poland.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
So I think that one of the exciting advances recently has been a lot of the new technology that it’s allowing us to understand things at greater resolution. And among those technologies include single-cell sequencing and even spatial technologies that are allowing us to look at individual cells. And so that has really sort of advanced our ability to be able to understand transformation, because transformation often consists of CLL cells and Richter cells within the same biopsy, so it gives us the opportunity to be able to understand the differences at new levels...
So I think that one of the exciting advances recently has been a lot of the new technology that it’s allowing us to understand things at greater resolution. And among those technologies include single-cell sequencing and even spatial technologies that are allowing us to look at individual cells. And so that has really sort of advanced our ability to be able to understand transformation, because transformation often consists of CLL cells and Richter cells within the same biopsy, so it gives us the opportunity to be able to understand the differences at new levels. And with those technologies and being able to apply them to these clinical situations, we’re starting to not only understand pathways and molecular features that are different between Richter’s and CLL, but that is sort of providing opportunity for us to understand features of the microenvironment that might be different and other things that may lead to sort of future disease targets.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
